Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel Free GNTA Stock Alerts

Genenta Science (GNTA) Financials

Genenta Science logo
$1.58 +0.03 (+1.94%)
Closing price 07/20/2026 04:00 PM Eastern
Extended Trading
$1.56 -0.02 (-0.95%)
As of 07:48 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Genenta Science

Annual Income Statements for Genenta Science

This table shows Genenta Science's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -5.16 -6.83 -6.26 -9.07 -13 -9.23 -7.58
Consolidated Net Income / (Loss)		 -5.16 -6.83 -6.26 -9.07 -13 -9.23 -7.66
Net Income / (Loss) Continuing Operations		 -5.16 -6.83 -6.26 -9.07 -13 -9.23 -7.66
Total Pre-Tax Income 		-5.16 -6.83 -6.26 -9.07 -13 -9.23 -7.66
Total Operating Income		 -5.19 -6.83 -6.44 -12 -13 -10 -7.75
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 5.19 6.83 6.44 12 13 10 7.75
Selling, General & Admin Expense		 1.03 1.10 2.60 6.10 5.82 5.13 4.58
Research & Development Expense		 4.16 5.73 3.84 5.71 7.16 4.98 3.17
Total Other Income / (Expense), net		 0.03 -0.00 0.18 2.75 0.10 0.88 0.09
Other Income / (Expense), net		 0.03 -0.00 0.18 2.75 -0.01 0.88 0.01
Income Tax Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 - - - - 0.02 - -0.08
Weighted Average Basic Shares Outstanding		 0.00 0.00 15.08M 18.22M 18.22M 18.29M 23.43M
Diluted Earnings per Share		 - - ($0.37) ($0.50) ($0.71) ($0.51) ($0.39)
Weighted Average Diluted Shares Outstanding		 - - 15.08M 18.22M 18.22M 18.27M 19.71M
Weighted Average Basic & Diluted Shares Outstanding		 - - - 18.22M 18.22M 18.29M 23.43M

Quarterly Income Statements for Genenta Science

No quarterly income statements for Genenta Science are available.

Annual Cash Flow Statements for Genenta Science

This table details how cash moves in and out of Genenta Science's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 14 -5.71 25 -7.96 -29 0.92 1.11
Net Cash From Operating Activities		 -2.79 -7.38 -7.88 -7.94 -12 -6.46 -8.06
Net Cash From Continuing Operating Activities		 -2.79 -7.38 -7.88 -7.94 -12 -6.46 -8.06
Net Income / (Loss) Continuing Operations		 -5.16 -6.83 -6.26 -9.07 -13 -9.23 -7.66
Consolidated Net Income / (Loss)		 -5.16 -6.83 -6.26 -9.07 -13 -9.23 -7.66
Depreciation Expense		 0.00 0.00 0.01 0.01 0.05 0.05 0.03
Non-Cash Adjustments To Reconcile Net Income		 0.60 0.22 0.58 0.87 0.90 1.12 1.42
Changes in Operating Assets and Liabilities, net		 1.76 -0.78 -2.20 0.26 -0.46 1.60 -1.85
Net Cash From Investing Activities		 0.00 -0.03 -0.01 -0.03 -16 7.12 -17
Net Cash From Continuing Investing Activities		 0.00 -0.03 -0.01 -0.03 -16 7.12 -17
Purchase of Property, Plant & Equipment		 0.00 -0.03 -0.01 -0.03 -0.02 -0.00 -0.01
Purchase of Investments		 - - 0.00 0.00 -16 -17 -39
Sale and/or Maturity of Investments		 - - - 0.00 0.00 24 22
Net Cash From Financing Activities		 17 1.70 33 0.00 0.00 0.28 26
Net Cash From Continuing Financing Activities		 17 1.70 33 0.00 0.00 0.28 26
Issuance of Debt		 - - - - 0.00 0.00 8.80
Issuance of Common Equity		 17 1.83 33 0.00 0.00 0.28 17
Effect of Exchange Rate Changes		 - - 0.00 0.00 -0.01 -0.02 0.08

Quarterly Cash Flow Statements for Genenta Science

No quarterly cash flow statements for Genenta Science are available.

Annual Balance Sheets for Genenta Science

This table presents Genenta Science's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 21 45 36 25 15 37
Total Current Assets		 20 44 34 24 15 35
Cash & Equivalents		 19 42 32 4.08 4.74 6.49
Short-Term Investments		 - 0.00 0.00 17 8.36 27
Prepaid Expenses		 1.31 1.72 2.06 2.74 1.88 2.15
Plant, Property, & Equipment, net		 0.02 0.03 0.12 0.09 0.04 0.03
Total Noncurrent Assets		 1.16 1.41 1.72 1.11 0.32 2.21
Other Noncurrent Operating Assets		 1.16 1.41 1.72 1.11 0.32 2.21
Total Liabilities & Shareholders' Equity		 21 45 36 25 15 37
Total Liabilities		 2.89 1.35 2.56 2.30 2.41 12
Total Current Liabilities		 2.85 1.28 2.34 1.92 2.17 2.49
Accounts Payable		 0.68 0.21 1.28 0.52 0.52 2.12
Accrued Expenses		 2.11 0.96 0.74 1.12 1.31 0.22
Other Current Liabilities		 0.07 0.11 0.32 0.28 0.35 0.14
Total Noncurrent Liabilities		 0.04 0.07 0.22 0.38 0.24 9.31
Noncurrent Employee Benefit Liabilities		 0.02 0.03 0.10 0.18 0.24 0.38
Other Noncurrent Operating Liabilities		 0.02 0.03 0.12 0.20 0.00 8.92
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 19 44 33 23 13 26
Total Preferred & Common Equity		 19 44 33 23 13 26
Total Common Equity		 19 44 33 23 13 26
Common Stock		 45 75 71 74 71 99
Retained Earnings		 -26 -31 -38 -52 -58 -73
Accumulated Other Comprehensive Income / (Loss)		 - 0.00 0.00 0.26 0.09 0.20

Quarterly Balance Sheets for Genenta Science

No quarterly balance sheets for Genenta Science are available.

Annual Metrics And Ratios for Genenta Science

This table displays calculated financial ratios and metrics derived from Genenta Science's official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 0.00 18,216,858.00 18,216,958.00 18,289,866.00 23,432,183.00
DEI Adjusted Shares Outstanding		 0.00 0.00 0.00 18,216,858.00 18,216,958.00 18,289,866.00 23,432,183.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 0.00 -0.50 -0.71 -0.50 -0.32
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -32.35% 8.44% -44.95% -42.75% 29.05% 16.07%
EBIT Growth		 0.00% -32.39% 8.39% -44.92% -43.17% 28.95% 16.14%
NOPAT Growth		 0.00% -31.58% 5.74% -83.55% -9.85% 22.13% 23.32%
Net Income Growth		 0.00% -32.39% 8.39% -44.92% -42.04% 28.39% 16.93%
EPS Growth		 0.00% 0.00% 0.00% -35.89% -40.81% 28.36% 23.64%
Operating Cash Flow Growth		 0.00% -164.22% -6.65% -0.77% -56.19% 47.89% -24.79%
Free Cash Flow Firm Growth		 0.00% 0.00% -53.36% -16.42% -20.24% 44.06% 134.42%
Invested Capital Growth		 0.00% 0.00% 544.73% -25.45% 22.99% -110.29% -4,260.18%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 99.21% 100.00% 99.05%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -36.91% -20.03% -23.47% -46.08% -51.92% -39.74%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -372.81% -497.29% -627.87% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% -36.91% -20.03% -23.47% -46.08% -51.92% -39.74%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -36.91% -14.23% -27.23% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.63 -4.78 -4.51 -8.27 -9.09 -7.07 -5.43
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% -21.69% -5.74% -2.16% -14.35% -12.63% -9.70%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -24.83% -40.20% -54.70% -21.17%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -5.16 -6.83 -6.26 -9.07 -13 -9.23 -7.74
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -5.16 -6.83 -6.25 -9.06 -13 -9.18 -7.70
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 1.49 0.60 3.01 3.99 6.13 1.06
Price to Tangible Book Value (P/TBV)		 0.00 1.49 0.60 3.01 3.99 6.13 1.06
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 50.91 42.05 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -1.02 -0.98 -0.96 -0.95 -0.96 -1.20
Leverage Ratio		 0.00 1.16 1.07 1.05 1.08 1.13 1.37
Compound Leverage Factor		 0.00 1.16 1.07 1.05 1.07 1.13 1.36
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 3.92 11.39 22.26 19.88 13.45 -0.99
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 0.00 7.09 34.15 14.53 12.25 6.89 14.16
Quick Ratio		 0.00 6.63 32.81 13.65 10.82 6.03 13.29
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -4.38 -6.71 -7.81 -9.39 -5.25 1.81
Operating Cash Flow to CapEx		 0.00% -28,961.76% -77,238.73% -27,404.36% -81,246.70% -139,658.47% -90,068.57%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 0.00 -0.40 1.80 1.34 1.65 -0.17 -7.40
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -0.40 2.20 -0.46 0.31 -1.82 -7.23
Enterprise Value (EV)		 0.00 8.71 -16 68 69 66 -5.78
Market Capitalization		 28 28 26 100 90 79 27
Book Value per Share		 $0.00 $7.71 $2.92 $1.83 $1.24 $0.71 $1.40
Tangible Book Value per Share		 $0.00 $7.71 $2.92 $1.83 $1.24 $0.71 $1.40
Total Capital		 0.00 19 44 33 23 13 26
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -19 -42 -32 -21 -13 -33
Capital Expenditures (CapEx)		 0.00 0.03 0.01 0.03 0.02 0.00 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -1.54 0.43 -0.27 0.82 -0.30 -0.34
Debt-free Net Working Capital (DFNWC)		 0.00 17 43 32 22 13 33
Net Working Capital (NWC)		 0.00 17 43 32 22 13 33
Net Nonoperating Expense (NNE)		 1.53 2.05 1.75 0.80 3.80 2.15 2.24
Net Nonoperating Obligations (NNO)		 0.00 -19 -42 -32 -21 -13 -33
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.01 0.01 0.05 0.05 0.03
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($0.37) ($0.47) ($0.64) $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 15.08M 18.22M 18.22M 18.29M 23.43M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($0.64) ($0.51) ($0.39)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 18.22M 18.22M 18.27M 19.71M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 18.22M 18.22M 18.29M 23.43M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.63 -4.78 -4.51 -8.27 -9.09 -7.07 -5.43
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -6.93% -1.22% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Genenta Science

No quarterly metrics and ratios for Genenta Science are available.


Financials Breakdown Chart

Genenta Science Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Genenta Science's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Genenta Science's net income appears to be on an upward trend, with a most recent value of -$7.66 million in 2025, rising from -$5.16 million in 2019. The previous period was -$9.23 million in 2024. Find out what analysts predict for Genenta Science in the coming months.

Genenta Science's total operating income in 2025 was -$7.75 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $7.75 million

Over the last 6 years, Genenta Science's total revenue changed from $0.00 in 2019 to $0.00 in 2025, a change of 0.0%.

Genenta Science's total liabilities were at $11.79 million at the end of 2025, a 389.3% increase from 2024, and a 307.6% increase since 2020.

In the past 5 years, Genenta Science's cash and equivalents has ranged from $4.08 million in 2023 to $42.15 million in 2021, and is currently $6.49 million as of their latest financial filing in 2025.

Over the last 6 years, Genenta Science's book value per share changed from 0.00 in 2019 to 1.40 in 2025, a change of 140.1%.


Related Companies

Financial statements for NASDAQ:GNTA last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Elon’s new "tollbooth"
The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...
Weiss Ratings | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel